Cover Image
市場調查報告書

精神分裂症(思覺失調症) : 開發中產品分析

Schizophrenia - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 232781
出版日期 內容資訊 英文 323 Pages
訂單完成後即時交付
價格
Back to Top
精神分裂症(思覺失調症) : 開發中產品分析 Schizophrenia - Pipeline Review, H2 2017
出版日期: 2017年10月31日 內容資訊: 英文 323 Pages
簡介

精神分裂症是會造成慢性嚴重腦功能障礙的疾病,一般症狀會在青年後期及成年早期出現。症狀有妄想、幻覺、支離破碎的會話及行動。危險因子有家族病史,年齡,藥物(精神活性藥),免疫系統低等。治療採用抗精神病藥。

本報告提供精神分裂症的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您夾雜了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。。

簡介

精神分裂症 概要

治療藥的開發

治療藥的評估

開發治療藥的企業

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9858IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia - Pipeline Review, H2 2017, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape.

Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. Risk factors include family history, age, drugs (psychoactive) and weakened immune system. Treatment includes antipsychotic medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Schizophrenia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Schizophrenia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 13, 13, 18, 1, 61, 9 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 8 and 2 molecules, respectively.

Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Schizophrenia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Schizophrenia (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Schizophrenia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents:

  • Table of Contents
  • Introduction
  • Schizophrenia - Overview
  • Schizophrenia - Therapeutics Development
  • Schizophrenia - Therapeutics Assessment
  • Schizophrenia - Companies Involved in Therapeutics Development
  • Schizophrenia - Drug Profiles
  • Schizophrenia - Dormant Projects
  • Schizophrenia - Discontinued Products
  • Schizophrenia - Product Development Milestones
  • Appendix

List of Tables:

  • Number of Products under Development for Schizophrenia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..6), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Schizophrenia - Pipeline by Acadia Pharmaceuticals Inc, H2 2017
  • Schizophrenia - Pipeline by Adamed Sp z oo, H2 2017
  • Schizophrenia - Pipeline by Aequus Pharmaceuticals Inc, H2 2017
  • Schizophrenia - Pipeline by AgeneBio Inc, H2 2017
  • Schizophrenia - Pipeline by Alkermes Plc, H2 2017
  • Schizophrenia - Pipeline by Astellas Pharma Inc, H2 2017
  • Schizophrenia - Pipeline by Athersys Inc, H2 2017
  • Schizophrenia - Pipeline by Avanir Pharmaceuticals Inc, H2 2017
  • Schizophrenia - Pipeline by Avineuro Pharmaceuticals Inc, H2 2017
  • Schizophrenia - Pipeline by BCWorld Pharm Co Ltd, H2 2017
  • Schizophrenia - Pipeline by BioCrea GmbH, H2 2017
  • Schizophrenia - Pipeline by BioHealthonomics Inc, H2 2017
  • Schizophrenia - Pipeline by Boehringer Ingelheim GmbH, H2 2017
  • Schizophrenia - Pipeline by Braeburn Pharmaceuticals Inc, H2 2017
  • Schizophrenia - Pipeline by Bristol-Myers Squibb Co, H2 2017
  • Schizophrenia - Pipeline by Curemark LLC, H2 2017
  • Schizophrenia - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017
  • Schizophrenia - Pipeline by Delpor Inc, H2 2017
  • Schizophrenia - Pipeline by Denovo Biopharma LLC, H2 2017
  • Schizophrenia - Pipeline by DURECT Corp, H2 2017
  • Schizophrenia - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Schizophrenia - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2017
  • Schizophrenia - Pipeline by Gabather AB, H2 2017
  • Schizophrenia - Pipeline by Galenea Corp, H2 2017
  • Schizophrenia - Pipeline by GeNeuro SA, H2 2017
  • Schizophrenia - Pipeline by GlaxoSmithKline Plc, H2 2017
  • Schizophrenia - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2017
  • Schizophrenia - Pipeline by GP Pharm SA, H2 2017
  • Schizophrenia - Pipeline by GW Pharmaceuticals Plc, H2 2017
  • Schizophrenia - Pipeline by H. Lundbeck A/S, H2 2017
  • Schizophrenia - Pipeline by Heptares Therapeutics Ltd, H2 2017
  • Schizophrenia - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2017
  • Schizophrenia - Pipeline by Indivior Plc, H2 2017
  • Schizophrenia - Pipeline by Insys Therapeutics Inc, H2 2017
  • Schizophrenia - Pipeline by IntelGenx Corp, H2 2017
  • Schizophrenia - Pipeline by Intra-Cellular Therapies Inc, H2 2017
  • Schizophrenia - Pipeline by IRLAB Therapeutics AB, H2 2017
  • Schizophrenia - Pipeline by Johnson & Johnson, H2 2017
  • Schizophrenia - Pipeline by JT Pharmaceuticals Inc, H2 2017
  • Schizophrenia - Pipeline by Karuna Pharmaceuticals Inc, H2 2017
  • Schizophrenia - Pipeline by KemPharm Inc, H2 2017
  • Schizophrenia - Pipeline by Kowa Co Ltd, H2 2017
  • Schizophrenia - Pipeline by Laboratorios Farmaceuticos Rovi SA, H2 2017
  • Schizophrenia - Pipeline by Lead Discovery Center GmbH, H2 2017
  • Schizophrenia - Pipeline by Lohocla Research Corp, H2 2017
  • Schizophrenia - Pipeline by Luye Pharma Group Ltd, H2 2017
  • Schizophrenia - Pipeline by Mapi Pharma Ltd, H2 2017
  • Schizophrenia - Pipeline by Merck & Co Inc, H2 2017
  • Schizophrenia - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017
  • Schizophrenia - Pipeline by Neurocrine Biosciences Inc, H2 2017
  • Schizophrenia - Pipeline by NeurOp Inc, H2 2017
  • Schizophrenia - Pipeline by Newron Pharmaceuticals SpA, H2 2017
  • Schizophrenia - Pipeline by Omeros Corp, H2 2017
  • Schizophrenia - Pipeline by Otsuka Holdings Co Ltd, H2 2017
  • Schizophrenia - Pipeline by Palo BioFarma SL, H2 2017
  • Schizophrenia - Pipeline by Peptron Inc, H2 2017
  • Schizophrenia - Pipeline by Pfizer Inc, H2 2017
  • Schizophrenia - Pipeline by Promentis Pharmaceuticals Inc, H2 2017
  • Schizophrenia - Pipeline by Ra Pharmaceuticals Inc, H2 2017
  • Schizophrenia - Pipeline by Reviva Pharmaceuticals Inc, H2 2017
  • Schizophrenia - Pipeline by Richter Gedeon Nyrt, H2 2017
  • Schizophrenia - Pipeline by Sage Therapeutics Inc, H2 2017
  • Schizophrenia - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017
  • Schizophrenia - Pipeline by SkySea Pharmaceutical Inc, H2 2017
  • Schizophrenia - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017
  • Schizophrenia - Pipeline by Sunovion Pharmaceuticals Inc, H2 2017
  • Schizophrenia - Pipeline by Suven Life Sciences Ltd, H2 2017
  • Schizophrenia - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2017
  • Schizophrenia - Pipeline by Tetra Discovery Partners LLC, H2 2017
  • Schizophrenia - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2017
  • Schizophrenia - Pipeline by Vanda Pharmaceuticals Inc, H2 2017
  • Schizophrenia - Pipeline by Vitality Biopharma Inc, H2 2017
  • Schizophrenia - Pipeline by VLP Therapeutics LLC, H2 2017
  • Schizophrenia - Pipeline by Zysis Ltd, H2 2017
  • Schizophrenia - Dormant Projects, H2 2017
  • Schizophrenia - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Schizophrenia - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Schizophrenia - Dormant Projects, H2 2017 (Contd..3), H2 2017
  • Schizophrenia - Dormant Projects, H2 2017 (Contd..4), H2 2017
  • Schizophrenia - Dormant Projects, H2 2017 (Contd..5), H2 2017
  • Schizophrenia - Dormant Projects, H2 2017 (Contd..6), H2 2017
  • Schizophrenia - Dormant Projects, H2 2017 (Contd..7), H2 2017
  • Schizophrenia - Discontinued Products, H2 2017
  • Schizophrenia - Discontinued Products, H2 2017 (Contd..1), H2 2017
  • Schizophrenia - Discontinued Products, H2 2017 (Contd..2), H2 2017

List of Figures:

  • Number of Products under Development for Schizophrenia, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top